Near-complete response to osimertinib in Stage IV lung adenocarcinoma with rare EGFR mutations

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR S768I mutation, PD-L1 TPS 2%

Metastatic Site: pleura, bone, lymph nodes

After progression on vinorelbine and carboplatin, osimertinib produced a metabolic complete response by December 2023 and a near-complete radiologic response in March 2024. He remained on osimertinib with good tolerance and stable clinical condition.

PubMed CentralRead more →

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

EGFR-mutated lung cancer treated with osimertinib during tuberculosis therapy

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, left axillary lymph node

Osimertinib maintained a partial response throughout 9 months of tuberculosis treatment, with no new abdominal or brain lesions. By the end of tuberculosis treatment, she was more than 7 years from her original lung-cancer diagnosis.

PubMed CentralRead more →

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed CentralRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Survivor Story

Patient Info: Daniel West, Male | Stage II

Biomarkers: EGFR alteration

At the latest report, Daniel had no evidence of active cancer; small lung nodules were being monitored without progression while he continued osimertinib.

Jeff

Patient Info: Jeff, Male | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain|bones|lymph nodes

The lung mass shrank, 5 brain lesions and the involved lymph node had no evidence of disease, and Jeff described his condition as stable while continuing osimertinib and bone-strengthening infusions.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Anne's Patient Story

Patient Info: Anne Laporte, Female | Stage IV

Biomarkers: EGFR-mutated; several additional mutations mentioned but not specified

Metastatic Site: Spine; liver; lymph nodes

As of March 2024, Anne was living with Stage IVB EGFR-mutated NSCLC on a clinical trial after progression on Tagrisso, with early signs of decreased tumor burden and major improvement in pain.

The Patient StoryRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR T790M mutation

Metastatic Site: Both lungs / bilateral lung nodules

As of March 2024, Ashley was living with Stage IV EGFR-mutated NSCLC controlled on daily Tagrisso for 43 months, with stable scans but no cancer-free or NED claim.

The Patient StoryRead more →

EGFR-mutated stage IV lung cancer complicated by radiation lung injury and severe COVID-19

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: bone

Osimertinib produced a significant reduction in the lung lesions. She remained alive at the last follow-up in July 2023 after recovering from severe COVID-19 and treatment-related lung complications.

PubMed CentralRead more →

Stage IV enteric-type lung adenocarcinoma with EGFR mutations and MSI-high disease

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; MSI-high; high tumor mutation burden; MLH1 mutation; pMMR; PD-L1-negative

Metastatic Site: lung, pleura

The cancer progressed through multiple targeted, chemotherapy, and immunotherapy regimens. He died about 30 months after the initial diagnosis.

PubMed CentralRead more →

Stage IV EGFR-Mutant Lung Adenocarcinoma Responding to Osimertinib

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR L833V/H835L mutations; PD-L1 50%; CDK4 amplification; MDM2 amplification

Metastatic Site: contralateral lung, brain

After 3 months of osimertinib, the right upper lobe lesion had decreased and right hilar lymphadenopathy had resolved. The brain lesion remained stable, and subsequent imaging continued to show improvement in the lung lesion.

PubMed CentralRead more →

Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue

Metastatic Site: thyroid; cervical lymph nodes

After starting osimertinib for EGFR exon 19-deleted recurrent lung adenocarcinoma, he was disease free 5 months after thyroid surgery.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Tiffany's Patient Story

Patient Info: Tiffany, Female | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: pelvis, right femur, cervical spine

As of March 2023, Tiffany had benefited from Tagrisso plus Cyramza, but later CT findings suggested worsening disease and she had started a new early-stage clinical trial with results pending.

The Patient StoryRead more →

Living with Cancer & My Survivorship : Lung Cancer

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: EGFR-positive; T790M mutation

As of September 2021, Ashley was living with incurable but treatable EGFR-positive T790M non-small cell lung cancer and described 43 months on treatment/journey while using community support to sustain hope.

The Patient StoryRead more →

Stage IV EGFR Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR-positive; T790M-positive

Metastatic Site: Not reported

As of September 2021, Ashley was living with incurable but treatable EGFR-positive/T790M-positive lung cancer on daily osimertinib/Tagrisso with ongoing oncology monitoring and side-effect management.

The Patient StoryRead more →

Cancer Survivor Story: How I Got Diagnosed with Lung Cancer

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: EGFR-positive; T790M mutation

Metastatic Site: Both lungs

As of August 2021, Ashley had been living for almost 4 years with incurable but treatable EGFR-positive T790M non-small cell lung cancer involving many tiny nodules across both lungs.

The Patient StoryRead more →

Facial paralysis from progression of EGFR-positive metastatic lung cancer improved with osimertinib

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: EGFR exon 21 p.Leu858Arg mutation.

Metastatic Site: brain; leptomeninges and facial nerves

Osimertinib rapidly resolved the bilateral facial weakness and reduced the brain lesions, but after 15 months seizures recurred and three smaller brain metastases had increased in size.

PubMed CentralRead more →

Stage IV EGFR-mutated lung cancer responding to osimertinib despite new lung opacities

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; EGFR T790M mutation

Metastatic Site: bilateral lungs

Over the following year on osimertinib, imaging showed an excellent tumour response with gradual improvement of the lung opacities and sustained clinical improvement.

PubMed CentralRead more →

Osimertinib rechallenge after severe pneumonitis in Stage IV lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, liver, bone, leptomeninges

She initially regained a significant response after osimertinib rechallenge without recurrent pneumonitis, but developed progressive leptomeningeal disease after 11 months.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ginger's Patient Story

Patient Info: Ginger Tam, Female | Stage IV

Biomarkers: EGFR mutation

Ginger lived for more than 5 years with metastatic lung cancer while receiving multiple research-driven treatments. She died on February 10, 2018.

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed CentralRead more →

EGFR-Mutated Stage IV Lung Adenocarcinoma With Painful Finger Lesions During Osimertinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR-mutated; EGFR T790M-positive at relapse

She remained on active osimertinib treatment; the finger lesions persisted but were controlled with colloidal oatmeal.

PubMed CentralRead more →

T790M-negative lung cancer on afatinib after AZD9291 trial ineligibility

Patient Info: Anonymized, Male

Biomarkers: T790M-negative blood test; EGFR/TKI treatment context

On 21 April 2016, the patient was not eligible for the AZD9291 trial because the blood sample was T790M-negative, so he continued afatinib/Giotrif while weighing future options and advance-care preferences.

Lung cancer on afatinib after liquid biopsy showed T790M resistance no longer detected

Patient Info: Anonymized, Male

Biomarkers: resistance to erlotinib no longer detected in latest liquid-biopsy blood sample

On 21 February 2016, the patient was continuing afatinib/Giotrif after liquid-biopsy monitoring no longer detected T790M resistance, while managing diarrhea, nausea, mucositis, and skin/eye irritation.